Complex underlying oncological disease with a visceral tumor entity (primary, metastases, recurrence): Colorectal (C18, C19, C20), pancreas (C25), esophagus (C15), stomach (C16), biliary tract and liver (C22.0/ C22.1, C23, C24), rare tumor entities
Conditions
Interventions
Group 1: Patients with a complex visceral oncological disease (primary, metastases, recurrence: colorectal (C18, C19, C20), pancreas (C25), esophagus (C15), stomach (C16), biliary tract and liver (C22
who will be presented in a new Cooperative Surgical Tumor Board (CoSITuB) as part of the study for consideration of surgical intervention and/or study participation and whose treatment pathway is moni
Sponsors
Technische Universität Dresden, Medizinische Fakultät Carl Gustav Carus, Klinik und Poliklinik für Viszeral-, Thorax- und Gefäßchirurgie
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: • Complex oncological disease, i.e. the extent or type of diagnosis or therapy of the oncological disease exceeds the capabilities of the treating medical facility and requires extended external, interdisciplinary consultation or requires the involvement of an expert center (NCT/UCCs) to provide the indicated treatment, according to the assessment of the on site physicians • Visceral tumor entity (primary, metastases, recurrence): colorectal (C18, C19, C20), pancreas (C25), esophagus (C15), stomach (C16), biliary tract and liver (C22.0/C22.1, C23, C24), rare tumor entities • Ability to consent • Ability to read and understand the German language • Being a registered patient with one of the five medical pilot partners in East Saxony
Exclusion criteria
Exclusion criteria: • Minors under the age of 18, • Patients who cannot read and understand the German language, • Patients who are unable to give consent, • pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is to create access for patients to the latest surgical techniques and to innovative studies in Eastern Saxony. After the baseline assessment, data collection takes place every three months. The following measuring instruments will be used: FACIT-TS-PS (version 4), CHAT (Collaboration Health Assessment Tool) , EORTC QLQ-C30 (version 3) and focus groups with treating physicians and study staff. | — |
Secondary
| Measure | Time frame |
|---|---|
| Subproject 1: • Clinical efficiency: complication rate, mortality rate, readmission rate • Patient satisfaction: treatment satisfaction, perceived quality of care, informed decision-making • Interdisciplinary cooperation: perceived quality, coordination and communication of the care processes • Efficiency of care processes: waiting and transfer times, completeness of pathway documentation, pathway deviations, efficiency of planning / reliability of decisions • Random survey of the population of oncology patients treated in one practice: number of patients not included in CoSITuB, diagnosis, surgical indication, mortality • Economic efficiency: length of hospital stay, duplication of findings Subproject 2: Utilization of CoSITuB: • Number and characteristics of cases presented, • time span between initial diagnosis and presentation to the tumor board, • time span between initial diagnosis and start of treatment/surgery, • comparison of first and second medical opinions regarding surgical indication/ resectability/ surgical procedure, • type and number of therapy changes, • type and number of surgical indications per site, • recording of the respective surgical procedures per site, • implementation of tumor board recommendations Timeframe of decision by CoSITuB, start of treatment and dispatch of medical letter at end of treatment Subproject 3: • Demographic data • Diagnosis (date of first diagnosis, ICD-10, stage, TNM, histology) • Secondary diagnosis (ICD-10) • Therapy (OPS codes, date, oncological systemic therapy) • Quality of life • Satisfaction of referring physician (with patient pathways, CoSITuB, the role of the FDN and the exchange and training program) Subproject 4: • Optimized communication (site visits, type and number of communication) • Screening for and enrollment in clinical trials • Use and evaluation of the training and exchange program Every three months patient satisfaction will be evaluated by using the | — |
Countries
Germany
Contacts
Public ContactChristin Richter
Technische Universität Dresden, Medizinische Fakultät Carl Gustav Carus, Klinik und Poliklinik für Viszeral-, Thorax- und Gefäßchirurgie
Outcome results
None listed